Literature DB >> 33716825

Human Laboratory Models of Cannabis Use: Applications for Clinical and Translational Psychiatry Research.

Reilly R Kayser1,2, Margaret Haney1,2, Helen Blair Simpson1,2.   

Abstract

Cannabis is increasingly used by individuals with mental health diagnoses and often purported to treat anxiety and various other psychiatric symptoms. Yet support for using cannabis as a psychiatric treatment is currently limited by a lack of evidence from rigorous placebo-controlled studies. While regulatory hurdles and other barriers make clinical trials of cannabis challenging to conduct, addiction researchers have decades of experience studying cannabis use in human laboratory models. These include methods to control cannabis administration, to delineate clinical and mechanistic aspects of cannabis use, and to evaluate potential treatment applications for cannabis and its constituents. In this paper, we review these human laboratory procedures and describe how each can be applied to study cannabis use in patients with psychiatric disorders. Because anxiety disorders are among the most common psychiatric illnesses affecting American adults, and anxiety relief is also the most commonly-reported reason for medicinal cannabis use, we focus particularly on applying human laboratory models to study cannabis effects in individuals with anxiety and related disorders. Finally, we discuss how these methods can be integrated to study cannabis effects in other psychiatric conditions and guide future research in this area.
Copyright © 2021 Kayser, Haney and Simpson.

Entities:  

Keywords:  anxiety disorders; cannabinoids; cannabis (marijuana); clinical and translational research; human laboratory research; psychiatric disorders

Year:  2021        PMID: 33716825      PMCID: PMC7947318          DOI: 10.3389/fpsyt.2021.626150

Source DB:  PubMed          Journal:  Front Psychiatry        ISSN: 1664-0640            Impact factor:   4.157


  113 in total

1.  Perspectives on Cannabis Research-Barriers and Recommendations.

Authors:  Margaret Haney
Journal:  JAMA Psychiatry       Date:  2020-10-01       Impact factor: 21.596

Review 2.  Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis.

Authors:  Jesse D Kosiba; Stephen A Maisto; Joseph W Ditre
Journal:  Soc Sci Med       Date:  2019-06-08       Impact factor: 4.634

Review 3.  A way forward for anxiolytic drug development: Testing candidate anxiolytics with anxiety-potentiated startle in healthy humans.

Authors:  Christian Grillon; Monique Ernst
Journal:  Neurosci Biobehav Rev       Date:  2020-10-07       Impact factor: 8.989

4.  Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress.

Authors:  Emma Childs; Joseph A Lutz; Harriet de Wit
Journal:  Drug Alcohol Depend       Date:  2017-05-30       Impact factor: 4.492

5.  Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.

Authors:  Margaret Haney; Ziva D Cooper; Gillinder Bedi; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin
Journal:  Neuropsychopharmacology       Date:  2013-02-26       Impact factor: 7.853

6.  Discriminative stimulus and subjective effects of smoked marijuana in humans.

Authors:  L D Chait; S M Evans; K A Grant; J B Kamien; C E Johanson; C R Schuster
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 7.  Medicinal Cannabis-Potential Drug Interactions.

Authors:  Muhammad A Alsherbiny; Chun Guang Li
Journal:  Medicines (Basel)       Date:  2018-12-23

8.  Previous cannabis exposure modulates the acute effects of delta-9-tetrahydrocannabinol on attentional salience and fear processing.

Authors:  Marco Colizzi; Philip McGuire; Vincent Giampietro; Steve Williams; Mick Brammer; Sagnik Bhattacharyya
Journal:  Exp Clin Psychopharmacol       Date:  2018-08-23       Impact factor: 3.157

9.  Attention-deficit-hyperactivity disorder and reward deficiency syndrome.

Authors:  Kenneth Blum; Amanda Lih-Chuan Chen; Eric R Braverman; David E Comings; Thomas J H Chen; Vanessa Arcuri; Seth H Blum; Bernard W Downs; Roger L Waite; Alison Notaro; Joel Lubar; Lonna Williams; Thomas J Prihoda; Tomas Palomo; Marlene Oscar-Berman
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

10.  Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis: A Crossover Trial.

Authors:  Tory R Spindle; Edward J Cone; Nicolas J Schlienz; John M Mitchell; George E Bigelow; Ronald Flegel; Eugene Hayes; Ryan Vandrey
Journal:  JAMA Netw Open       Date:  2018-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.